You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Start today for a better tomorrow
Start today for a better tomorrow

Start today to improve the lives of your patients with moderate to severe LUTS/BPH

LUTS: Lower urinary tract symptoms; BPH: Benign prostatic hyperplasia

LUTS/BPH treatment goals

Evolving optimal treatment goals include relieving bothersome symptoms, alteration of disease progression and prevention of complications associated with LUTS/BPH.

Identify LUTS/BPH patients at risk of disease progression first, to select optimal therapy

duodartimage1
duodartimage2
duodart_packshot

About Duodart

Duodart is indicated for the treatment of patients with moderate-to-severe symptoms of Benign Prostatic Hyperplasia (BPH).

It reduces the risk of acute urinary retention (AUR) and the need for BPH-related surgery by reducing prostate size, improving urinary flow and alleviating symptoms.1

An effective and simple solution1

Dosing is simple:

One capsule
One dose
Once daily, 30 minutes after food.*
*The same meal every day

Dosage and administration

Notes

Dutasteride 0.5 mg plus tamsulosin hydrochloride 0.4 mg

One capsule, once daily, swallowed (not chewed)

Taken at the same time each day, 30 minutes after food.

The capsules should be swallowed whole and not chewed or opened. Contact with the contents of the dutasteride capsule contained within the hard-shell capsule may result in irritation of the oropharyngeal mucosa

Duodart should not be taken on an empty stomach

The effect of renal impairment on dutasteride-tamsulosin pharmacokinetics has not been studied. However, no adjustment in dosage is anticipated for patients with renal impairment

Results indicated that no dutasteride dose adjustment based on age is necessary

Some men notice an early improvement in symptoms with Duodart, however others need to continue for at least 6 months to see if response can be achieved

Patients must continue to take their medication as symptoms improve.

 

For more information about dosing, see the Duodart prescribing information.

Duodart is a combination of 2 drugs with complementary mechanisms of action:1

  • The dual 5-alpha-reductase inhibitor dutasteride inhibits Type I and Type II 5-alpha-reductase isoenzymes, which convert testosterone to 5-alpha-dihydrotestosterone (DHT), the androgen primarily responsible for hyperplasia of glandular prostatic tissue
  • The alpha-1-adrenergic blocker tamsulosin hydrochloride, which inhibits alpha-adrenergic receptors in prostatic smooth muscle and bladder neck.
dutasteride_image

Dutasteride:

  • Lowers DHT levels
  • Reduces prostate volume
  • Improves lower urinary tract symptoms and urinary flow
  • Reduces the risk of AUR and BPH-related surgery.
  • Tamsulosin hydrochloride inhibits alpha-1A-adrenergic receptors in the stromal prostatic smooth muscle and bladder neck. Approximately 75% of the alpha-1-receptors in the prostate are of the alpha-1A subtype.

Tamsulosin hydrochloride:

  • Reduces smooth muscle tension in the prostate and urethra
  • Increases maximum urinary flow rate
  • Relieves obstruction
  • Improves irritative and obstructive symptoms
  • Lowers peripheral resistance

Safety Information for DUODART

  • Adverse events associated with Duodart include impotence, decreased libido, ejaculation disorders, breast tenderness and enlargement, and dizziness.
  • Men taking Duodart should be regularly evaluated for prostate cancer risk including PSA testing. Any confirmed increase from lowest PSA level while on Duodart may signal the presence of prostate cancer or noncompliance to therapy with Duodart and should be carefully evaluated.
  • For additional/complete safety information, please refer to the prescribing information for Duodart
  • Clinical trials events and post-marketing reports of congestive heart failure, male breast cancer and high grade prostate cancer have occurred, although a causal relationship with Duodart has not been established. Alpha blockers have been associated with risk of orthostatic hypotension and intraoperative floppy iris syndrome.
  • Duodart is contraindicated in women, children, patients with hypersensitivity to 5-alpha reductase inhibitors, tamsulosin, or any of the other excipients;

Find out more about Duodart

References

  1. DUODART prescribing information.
  2. Gravas S, et al. Guidelines on management of male LUTS, incl BPO. 2017. http://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts. Accessed 6 February 2018.

PM-NG-DTT-WCNT-220001 Date of Preparation: May 2022